Newborn screening and pediatric test developer Baebies has received a CE mark for assays that screen for two genetic disorders.

The galactosemia and biotinidase deficiency assays, which run on the company’s Seeker screening platform, use dried blood-spot specimens to detect reduced enzyme activity in newborns.

The Durham, N.C.-based company is launching the assays in Europe and other countries that recognize the CE mark.